In building its COVID-19 pandemic products empire, Pfizer has steered relatively clear of controversy as it has developed vaccines and treatments quickly and manufactured them with remarkable efficiency.
(Bloomberg) -- Pfizer Inc. has picked a Chinese drug-making giant once embroiled in a global medicines recall for supplying tainted ingredients to make its Covid-19 antiviral pill in the country.
Viatris launched its Biocon-partnered Lantus biosimilar—in two versions. Growth from AstraZeneca's star China unit slowed to just 2% amid major price cuts to EGFR lung cancer drug Tagrisso. Zhejiang Huahai Pharmaceutical, the protagonist in a global valsartan recall three years ago, has come off an FDA warning letter. And more.
The FDA has now closed a warning letter that was slapped on Zhejiang Huahai Pharmaceutical’s Chuannan site in Taizhou, the agency recently disclosed.
Zhejiang Huahai Pharma Receives FDA Warning Letter
Following its investigation into an impurity called N-nitrosodimethylamine (NDMA) in blood pressure medicines, the EMA on Friday said that, at the request of the European Commission, it’s beginning a review of ranitidine medicines after tests showed that some contained the impurity.
US officials worried about Chinese control of American drug supply
Following its investigation into an impurity called N-nitrosodimethylamine (NDMA) in blood pressure medicines, the European Medicines Agency (EMA) on Friday said that, at the request of the European Commission, it’s beginning a review of ranitidine medicines after tests showed that some contained the impurity.
The fallout from the N-Nitrosodiethylamine (NDEA) and N-Nitrosodimethylamine (NDMA) impurities fiasco continues as the US Food and Drug Administration (FDA) last week sent a warning letter to India-based Lantech Pharmaceuticals.
Fourth Carcinogen Discovered in Heart Pills Used by Millions